✦ LIBER ✦

Cost-effectiveness analysis of lamivudine and adefovir dipivoxil in the treatment of patients with HBeAg-negative chronic hepatitis B

✍ Scribed by M. BUTI; M. A. CASADO; J. L. CALLEJA; J. SALMERÓN; J. AGUILAR; M. RUEDA; R. ESTEBAN

Book ID: 108604415
Publisher: John Wiley and Sons
Year: 2006
Tongue: English
Weight: 151 KB
Volume: 23
Category: Article
ISSN: 0269-2813
DOI: 10.1111/j.1365-2036.2006.02767.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Extended treatment with lamivudine and a

Extended treatment with lamivudine and adefovir dipivoxil in chronic hepatitis B patients with lamivudine resistance

✍ Robert P. Perrillo; Hie-Won Hann; Eugene Schiff; David Mutimer; Bernard Willems; 📂 Article 📅 2011 🏛 Springer-Verlag 🌐 English ⚖ 309 KB

Adefovir dipivoxil added to ongoing lami

Adefovir dipivoxil added to ongoing lamivudine therapy in patients with lamivudine-resistant hepatitis B e antigen-negative chronic hepatitis B

✍ T. Vassiliadis; N. Nikolaidis; O. Giouleme; K. Tziomalos; N. Grammatikos; K. Pat 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 90 KB

Factors contributing to antiviral effect

Factors contributing to antiviral effect of adefovir dipivoxil therapy added to ongoing lamivudine treatment in patients with lamivudine-resistant chronic hepatitis B

✍ Nao Kurashige; Naoki Hiramatsu; Kazuyoshi Ohkawa; Takayuki Yakushijin; Shinichi 📂 Article 📅 2009 🏛 Springer Japan 🌐 English ⚖ 321 KB

De novo combination of lamivudine and ad

De novo combination of lamivudine and adefovir versus entecavir monotherapy for the treatment of naïve HBeAg-negative chronic hepatitis B patients

✍ Li-Chun Wang; En-Qiang Chen; Jing Cao; Li Liu; Li Zheng; Da-Jiang Li; Lu Xu; Xue 📂 Article 📅 2011 🏛 Springer-Verlag 🌐 English ⚖ 243 KB

Increased risk of adefovir resistance in

Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy

✍ Yoon-Seon Lee; Dong Jin Suh; Young-Suk Lim; Suk Won Jung; Kang Mo Kim; Han Chu L 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 239 KB

Although adefovir dipivoxil (ADV) has a unique profile of delayed and infrequent resistance in treatment-naïve chronic hepatitis B patients, the association of ADV resistance with previous lamivudine (LAM) resistance is not well understood. We compared the emergence of the ADV-resistant mutations rt

Mutations associated with the therapeuti

Mutations associated with the therapeutic efficacy of adefovir dipivoxil added to lamivudine in patients resistant to lamivudine with type B chronic hepatitis

✍ Kazuyoshi Ohkawa; Tetsuo Takehara; Michio Kato; Aimi Kanada; Matsuo Deguchi; Mas 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 269 KB

## Abstract Factors influencing the therapeutic efficacy of adefovir dipivoxil added to continuing lamivudine have not been elucidated in lamivudine‐resistant patients with type B chronic hepatitis. The viral mutations influencing the efficacy of treatment with adefovir dipivoxil were investigated